Lucy Scientific Discovery (NASDAQ:LSDI – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Earnings & Valuation
This table compares Lucy Scientific Discovery and Janux Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucy Scientific Discovery | $16,732.00 | 89.24 | -$8.99 million | ($7.00) | -0.12 |
| Janux Therapeutics | $8.08 million | 333.30 | -$58.29 million | ($1.34) | -38.76 |
Lucy Scientific Discovery has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Lucy Scientific Discovery, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Lucy Scientific Discovery | N/A | -294.74% | -137.65% |
| Janux Therapeutics | -721.18% | -17.88% | -15.95% |
Risk & Volatility
Lucy Scientific Discovery has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.87, meaning that its stock price is 287% more volatile than the S&P 500.
Insider & Institutional Ownership
72.6% of Lucy Scientific Discovery shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 35.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Lucy Scientific Discovery and Janux Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucy Scientific Discovery | 0 | 0 | 1 | 0 | 3.00 |
| Janux Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Janux Therapeutics has a consensus price target of $64.83, suggesting a potential upside of 24.82%. Given Janux Therapeutics’ higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Lucy Scientific Discovery.
Summary
Janux Therapeutics beats Lucy Scientific Discovery on 10 of the 13 factors compared between the two stocks.
About Lucy Scientific Discovery
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
About Janux Therapeutics
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Receive News & Ratings for Lucy Scientific Discovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucy Scientific Discovery and related companies with MarketBeat.com's FREE daily email newsletter.
